sever
year
overus
acut
medic
burstein
cowork
assess
develop
cutan
allodynia
might
sign
progress
within
attack
show
cutan
allodynia
develop
peopl
migrain
first
hour
attack
reach
maxim
sever
h
onset
absenc
cutan
allodynia
patient
treat
triptan
pain
free
within
h
compar
treat
cutan
allodynia
addit
insight
effect
use
exist
acut
treatment
new
acut
treatment
mechan
emerg
calcitonin
generel
peptid
cgrp
long
play
promin
role
model
migrain
pathogenesi
inhibit
cgrp
caus
littl
vasoconstrict
approach
may
provid
acut
treatment
without
problem
associ
vasoconstriciton
olesen
colleagu
studi
bibn
bs
highli
specif
potent
nonpeptid
cgrpreceptor
antagonist
acut
treatment
migrain
mg
intraven
dose
associ
respons
rate
compar
placebo
respons
treatment
better
placebo
secondari
endpoint
well
sideeffect
appropri
deliveri
system
develop
approach
may
enabl
acut
treatment
without
problem
vasoconstrict
vcjd
lethal
diseas
affect
young
peopl
rapidli
emerg
part
famili
transmiss
spongiform
encephalopathi
rare
fatal
neurodegen
diseas
human
be
anim
includ
kuru
scrapi
chronic
wast
diseas
characteris
accumul
brain
insolubl
proteaseresist
isoform
hostencod
cellular
prion
protein
past
year
diseas
becom
major
agricultur
econom
threat
late
product
protein
supplement
livestock
anim
carcass
link
transmiss
bovin
spongiform
encephalopathi
outbreak
dairi
cow
human
be
develop
vcjd
health
concern
rais
diseas
cross
speci
barrier
cattl
human
be
adapt
differ
mammalian
speci
diagnost
criteria
vcjd
formul
mri
show
high
signal
posterior
thalamu
peopl
vcjd
subclin
infect
preced
overt
diseas
research
focus
develop
sensit
assay
detect
minut
amount
prion
protein
suspect
case
proteom
immunolog
patholog
molecular
approach
diagnosi
develop
refin
research
led
identif
second
transmiss
spongiform
encephalopathi
cattl
characteris
presenc
prionproteinimmunoposit
amyloid
plaqu
similar
sporad
cjd
bioterror
potenti
caus
lethal
neurolog
infect
research
pathogenesi
immun
respons
organ
possibl
terrorist
weapon
howev
need
joint
effort
among
pharmaceut
biotechnolog
industri
parallel
government
respons
toward
antivir
discoveri
yet
realis
posit
note
action
taken
erad
sever
deadli
infect
nervou
system
three
pivot
research
front
therapeut
prevent
vaccin
microbi
detect
remark
advanc
prevent
nervou
system
infect
vaccin
deliveri
global
erad
campaign
erad
poliomyel
involv
vaccin
billion
children
reduc
global
incid
polio
case
less
polio
like
elimin
within
next
year
introduct
vaccin
serotyp
pneumococcu
neisseria
mening
meningococcu
substanti
reduc
case
mening
former
incid
invas
pneumococc
diseas
children
age
year
europ
case
per
meningococcu
lead
caus
mening
fulmin
septicaemia
worldwid
epidem
subsaharan
africa
incid
case
per
peopl
occur
epidem
sever
west
african
countri
caus
nearli
death
anoth
major
epidem
happen
meningococc
serogroup
b
c
associ
morbitiy
mortal
meningococc
polysaccharid
vaccin
either
bival
group
c
tetraval
group
c
conjug
vaccin
meningococcu
serotyp
c
notic
reduc
diseas
incid
global
elimin
bacteri
mening
may
achiev
vaccin
serotyp
avail
largescal
synthesi
pharmaceut
develop
clinic
assess
conjug
haemophilu
influenza
type
b
hib
vaccin
possibl
research
show
access
synthet
complex
carbohydratebas
vaccin
feasibl
provid
platform
vaccin
deliveri
develop
world
inde
infant
death
occur
annual
develop
countri
result
hibinduc
mening
pneumonia
use
hib
polysaccharid
requir
technolog
restrict
global
access
much
need
vaccin
face
revolut
infecti
diseas
occurr
persist
research
advanc
diagnost
therapeut
produc
substanti
accomplish
global
public
health
center
neurovirolog
neurodegen
disord
depart
pharmacolog
patholog
microbiolog
univers
nebraska
medic
center
omaha
ne
usa
hegendel
unmcedu
conflict
interest
